Related Experiment Video
Updated: Mar 31, 2026
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study
Hsin-Hsu Chou1, Mei-Ju Chen2, Yuan-Yow Chiou3,4
1Department of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan, ROC.
Insights
Enteric-coated mycophenolate sodium (EC-MPS) improved survival and response rates in pediatric lupus nephritis (LN) patients. This treatment showed efficacy without increasing complications, suggesting it is a viable option for pediatric LN management.
Area of Science:
- Pediatric Nephrology
- Immunosuppressive Therapy
- Autoimmune Diseases
Background:
- Pediatric lupus nephritis (LN) requires effective long-term treatment.
- Enteric-coated mycophenolate sodium (EC-MPS) is a potential therapeutic agent.
Purpose of the Study:
- To evaluate the long-term efficacy of EC-MPS in pediatric LN.
- To assess complications associated with EC-MPS treatment in this population.
Main Methods:
- Retrospective analysis of pediatric patients with LN from 1995-2008.
- Comparison between patients treated with EC-MPS (MPS group) and those not (non-MPS group).
- Primary endpoint: survival; Secondary endpoint: time to stage 3 chronic kidney disease (CKD).
Main Results:
- The MPS group (33 patients) showed significantly higher complete/partial response rates (72.7% vs. 31.6%) and survival (100% vs. 42.1%) compared to the non-MPS group (19 patients).
- No significant difference in the rate of stage 3 CKD between groups.
- Similar incidence of complications, including gastrointestinal issues, across both groups.
Conclusions:
- Despite limitations like treatment timing heterogeneity, EC-MPS appears effective for pediatric LN.
- EC-MPS demonstrates a favorable risk-benefit profile for managing pediatric lupus nephritis.
Background:
The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN).
Methods:
This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined.
Results:
There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications.
Conclusion:
A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.
More Related Videos
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:29Drugs for Treatment of Ulcerative Colitis in IBD